Bispecific ADC “Really Strong” against ESCC

A phase I study of the bispecific antibody–drug conjugate BL-B01D1 shows encouraging safety and effectiveness. The drug, which targets EGFR and HER3, triggered side effects in most patients, but at the higher of two doses tested, it spurred tumor responses in almost 40% of patients.

Authors

Publication Details

Journal
Cancer Discovery
Published
2025-01-01
DOI
https://doi.org/10.1158/2159-8290.cd-nw2025-0064
Primary Topic
Chemistry and Chemical Engineering
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Bispecific ADC “Really Strong” against ESCC

Mitch Leslie
Cancer Discovery
Chemistry and Chemical Engineering
article

Bispecific ADC “Really Strong” against ESCC

Mitch Leslie
article en

Abstract

A phase I study of the bispecific antibody–drug conjugate BL-B01D1 shows encouraging safety and effectiveness. The drug, which targets EGFR and HER3, triggered side effects in most patients, but at the higher of two doses tested, it spurred tumor responses in almost 40% of patients.

Cancer Discovery
Reduced inequalities
Openalex Percentile: Top 83%
Chemistry and Chemical Engineering
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Bispecific ADC “Really Strong” against ESCC — Mitch Leslie · Cancer Discovery (2025) | TGRS Research Map | TGRS